Next Article in Journal
Development of a Universal Epitope-Based Influenza Vaccine and Evaluation of Its Effectiveness in Mice
Previous Article in Journal
Development of Flat Warts on the Cheeks after BioNTech-Pfizer BNT162b2 Vaccine: Is There a Correlation?
Previous Article in Special Issue
Utilization of Viral Vector Vaccines in Preparing for Future Pandemics
 
 
Article

Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein

1
Institute of Virology, Philipps University Marburg, 35043 Marburg, Germany
2
German Center for Infection Research, Partner Site Giessen-Marburg-Langen, 35043 Marburg, Germany
3
Institute of Virology, University of Veterinary Medicine Hannover, 30559 Hannover, Germany
4
German Center for Infection Research, Partner Site Munich, 80539 Munich, Germany
5
Division of Virology, Institute for Infectious Diseases and Zoonoses, LMU Munich, 80539 Munich, Germany
6
Institute of Veterinary Pathology, Justus Liebig University Giessen, 35392 Giessen, Germany
*
Author to whom correspondence should be addressed.
Academic Editors: Markus Kainulainen and Anthony Griffiths
Vaccines 2022, 10(4), 533; https://doi.org/10.3390/vaccines10040533
Received: 24 February 2022 / Revised: 23 March 2022 / Accepted: 25 March 2022 / Published: 29 March 2022
(This article belongs to the Special Issue A Modern Take on Replicating Viral Vaccines)
The urgent need for vaccines against Ebola virus (EBOV) was underscored by the large outbreak in West Africa (2014–2016). Since then, several promising vaccine candidates have been tested in pre-clinical and clinical studies. As a result, two vaccines were approved for human use in 2019/2020, of which one includes a heterologous adenovirus/Modified Vaccinia virus Ankara (MVA) prime-boost regimen. Here, we tested new vaccine candidates based on the recombinant MVA vector, encoding the EBOV nucleoprotein (MVA-EBOV-NP) or glycoprotein (MVA-EBOV-GP) for their efficacy after homologous prime-boost immunization in mice. Our aim was to investigate the role of each antigen in terms of efficacy and correlates of protection. Sera of mice vaccinated with MVA-EBOV-GP were virus-neutralizing and MVA-EBOV-NP immunization readily elicited interferon-γ-producing NP-specific CD8+ T cells. While mock-vaccinated mice succumbed to EBOV infection, all vaccinated mice survived and showed drastically decreased viral loads in sera and organs. In addition, MVA-EBOV-NP vaccinated mice became susceptible to lethal EBOV infection after depletion of CD8+ T cells prior to challenge. This study highlights the potential of MVA-based vaccines to elicit humoral immune responses as well as a strong and protective CD8+ T cell response and contributes to understanding the possible underlying mechanisms. View Full-Text
Keywords: Ebola virus; Modified Vaccinia virus Ankara; vaccine; correlates of protection; nucleoprotein; glycoprotein Ebola virus; Modified Vaccinia virus Ankara; vaccine; correlates of protection; nucleoprotein; glycoprotein
Show Figures

Figure 1

MDPI and ACS Style

Kupke, A.; Volz, A.; Dietzel, E.; Freudenstein, A.; Schmidt, J.; Shams-Eldin, H.; Jany, S.; Sauerhering, L.; Krähling, V.; Gellhorn Serra, M.; Herden, C.; Eickmann, M.; Becker, S.; Sutter, G. Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein. Vaccines 2022, 10, 533. https://doi.org/10.3390/vaccines10040533

AMA Style

Kupke A, Volz A, Dietzel E, Freudenstein A, Schmidt J, Shams-Eldin H, Jany S, Sauerhering L, Krähling V, Gellhorn Serra M, Herden C, Eickmann M, Becker S, Sutter G. Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein. Vaccines. 2022; 10(4):533. https://doi.org/10.3390/vaccines10040533

Chicago/Turabian Style

Kupke, Alexandra, Asisa Volz, Erik Dietzel, Astrid Freudenstein, Jörg Schmidt, Hosam Shams-Eldin, Sylvia Jany, Lucie Sauerhering, Verena Krähling, Michelle Gellhorn Serra, Christiane Herden, Markus Eickmann, Stephan Becker, and Gerd Sutter. 2022. "Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein" Vaccines 10, no. 4: 533. https://doi.org/10.3390/vaccines10040533

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop